By vgreene, 28 October, 2021 Treating COVID 19 With Chloroquine vs LPV r access J Mol Cell Biol article
By vgreene, 28 October, 2021 Efficacy and Safety of Lopinavir Ritonavir or Arbidol in Adult Patients With Mild Moderate COVID 19 An Exploratory Randomized Controlled Trial access Med article
By vgreene, 28 October, 2021 Arbidol Monotherapy Is Superior to Lopinavir Ritonavir in Treating COVID 19 access J Infect article
By vgreene, 28 October, 2021 Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID 19 The TOGETHER Randomized Clinical Trial access JAMA Network Open article
By vgreene, 28 October, 2021 Study considerations randomized interim analysis significant proportion of pts received other potential treatments for COVID varied by tx arm sx duration not reported excluded peds pts
By vgreene, 28 October, 2021 Overall 28 day mortality 12 no significant difference in reduced mortality w death rate ratio vs control RDV RR 0 95 95 CI 0 81 1 11 HCQ RR 1 19 95 CI 0 89 1 59 LPV r RR 1 00 95 CI 0 79 1 25 and IFN RR 1 16 95 CI 0 96 1 39 no significant difference in ven
By vgreene, 28 October, 2021 Multinational randomized study 11 266 hospitalized pts 10 ventilated w COVID 19 received either RDV n 2 750 HCQ n 954 LPV r n 1 411 IFN beta 1a LPV r n 651 IFN beta 1a n 1 412 or SOC n 4 088 pts could receive other therapies incl CS immunomodulators and o
By vgreene, 28 October, 2021 Study considerations not peer reviewed randomized interim analysis significant proportion of pts received other potential treatments for COVID varied by tx arm sx duration not reported excluded peds pts
